SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its manufacturing partner, JOINN Biologics, has successfully completed production of the FL115 pivotal batch, which will support the company’s upcoming Phase III clinical trial in non-muscle invasive bladder cancer (NMIBC).FL115 is an engineered IL-15/IL-15Rα-Fbody® fusion protein. Fbo